KERYX BIOPHARMACEUTICALS INC

Form 8-K June 06, 2008

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 5, 2008

Keryx Biopharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation)

000-30929 (Commission File Number)

13-4087132 (IRS Employer Identification No.)

750 Lexington Avenue New York, New York 10022

(Address of Principal Executive Offices)

(212) 531-5965

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- £ Written communications pursuant to Rule 425 under the Securities Act.
 - £ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
- £ Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
- £ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

Item 5.02.	Departure of Directors or Certain Officers; Election of Directors;	Appointment of Certain Officers;
	Compensatory Arrangements of Certain Officers.	

(b)	On June 5, 2008, Beth F. Levine, Senior Vice President, General Counsel, Chief Compliance Officer and
	Corporate Secretary of Keryx Biopharmaceuticals, Inc. (the "Company"), submitted her resignation to the
	Company. The resignation will be effective on June 27, 2008.

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Keryx Biopharmaceuticals, Inc.

(Registrant)

Date: June 6, 2008 By: /s/ James F. Oliviero

James F. Oliviero Vice President, Finance